Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.47 |
| ▸ | TNKS | O95271 | 3/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19107362 | 0.92 | PIK3CA (0.44) | PARP1TNKSTNKS2HDAC2HDAC1 | |
| SCHEMBL17328258 | 0.87 | PARP1 (0.47) | PARP1TNKSTNKS2GPR119PIK3CA | |
| SCHEMBL19107364 | 0.85 | PARP1 (0.43) | PARP1TNKSTNKS2HDAC2HDAC1 | |
| SCHEMBL19107360 | 0.85 | MEN1 (0.48) | HDAC2HDAC1GPR119RORC | |
| SCHEMBL19107363 | 0.83 | MAPK1 (0.50) | SMN1; SMN2LMNA | |
| SCHEMBL19107356 | 0.83 | HPGD (0.46) | PARP1TNKSTNKS2GPR119RORC | |
| SCHEMBL3089588 | 0.83 | MEN1 (0.52) | PARP1TNKSTNKS2GPR119SMN1; SMN2 | |
| SCHEMBL17328248 | 0.82 | EPHX2 (0.45) | PARP1GPR119RORCLMNA | |
| SCHEMBL19107359 | 0.80 | PARP1 (0.45) | PARP1TNKSTNKS2GPR119MAPT | |
| SCHEMBL19120395 | 0.80 | HTT (0.48) | SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3149005-B1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE LABOR DR (ES) | 2018-04-18 | — | — | EP | disclosed |
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-07-13 | — | — | US | disclosed |
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRM1 | PARP1 2078/4885TNKS 3507/4885TNKS2 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.